Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Multi-Center, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumors or B-cell Lymphoma

NCT04418141 is registered in ClinicalTrials.gov with Curon Biopharmaceutical (Australia) Co Pty Ltd as lead sponsor.

NCT NCT04418141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04418141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Multi-Center, Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 in Patients With Advanced Solid Tumors or B-cell Lymphoma
Lead sponsor
Curon Biopharmaceutical (Australia) Co Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
July 2, 2020
Completion date
October 7, 2021
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, b cell lymphoma